^
    Back
    Association details:
    Biomarker:EGFR E709K
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Biomed J
    Title:

    Early Radiographic Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutations: A Prospective Study

    Excerpt:
    Table 2: Clinical features of 39 adenocarcinoma patients of lung treated with EGFR‑TKI....In conclusion, this prospective study demonstrated a high correlation (72.4%) in the radiological response between early (Day 14) and regular evaluation time (Day 56), and a very high percentage (21/29, 72.4%) of early radiological response to EGFR‑TKIs in NSCLC patients with EGFR mutations and PR, which would advocate early radiological examination for EGFR‑TKI therapy in NSCLC patients.
    DOI:
    10.4103/2319-4170.138320